Responding to this week’s news about two experimental drug treatments showing encouraging survival results to treat the Ebola virus now being used in a critical trial in the Democratic Republic of Congo, Argonne National Laboratory Distinguished Fellow Andrzej Joachimiak can speak as an expert source in connection with this work.
One of the treatments, a monoclonal antibody called mAb114, was developed using antibodies harvested from survivors of Ebola infection. The crystal structures research was conducted at the Advanced Photon Source (APS), a U.S. Department of Energy Office of Science User Facility at Argonne. The APS is one of the most powerful synchrotron X-ray facilities in the world and provides researchers with extremely bright high-energy, storage-ring based X-rays up to one billion times brighter than the X-rays produced in a typical dentist office. Researchers come from around the world to conduct lifesaving research at the APS.
RSS